12.25MMarket Cap-300P/E (TTM)
8.2000High6.6000Low212.57KVolume6.7500Open6.7500Pre Close1.57MTurnover34.66%Turnover RatioLossP/E (Static)1.58MShares64.890052wk High8.63P/B4.74MFloat Cap4.432052wk Low--Dividend TTM613.38KShs Float2568.3000Historical High--Div YieldTTM23.70%Amplitude4.4320Historical Low7.3710Avg Price1Lot Size
Vaccinex Stock Forum
$Dow Jones Industrial Average(.DJI.US)$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US)$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US)$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US)$, $Johnson & Johnson(JNJ.US)$, and $Cisco(CSCO.US)$ l...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinema...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
Anybody have some idea or clue as to the runnings on these docs so when you do come in please, can you include your best entry and exit strategies on the stock
No comment yet